Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-04-30, Stock:ABBV, The news for the past five days is as follows:
2018-04-23: NEWS1: Is a Beat in Store for Alexion (ALXN) This Earnings Season?.NEWS2: Is a Beat in Store for Alexion (ALXN) This Earnings Season?.NEWS3: What Lies Ahead for Vice ETFs?.NEWS4: What Lies Ahead for Vice ETFs?.NEWS5: Johnson & Johnson’s Revenues Continued to Rise in 1Q18.NEWS6: Amid drug price worries, earnings to test U.S. pharma, biotech shares.NEWS7: Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy.NEWS8: Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy.NEWS9: Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings?.NEWS10: Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings?.NEWS11: Will Global Industrial Unit Boost Ecolab's (ECL) Q1 Earnings?.NEWS12: Will Global Industrial Unit Boost Ecolab's (ECL) Q1 Earnings?.NEWS13: Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy.NEWS14: 5 Dividend Growth Stocks With Upside To Analyst Targets.NEWS15: 5 Dividend Growth Stocks With Upside To Analyst Targets.NEWS16: Implied DIVB Analyst Target Price: $29.NEWS17: Implied DIVB Analyst Target Price: $29.
2018-04-24: NEWS1: U.S. Supreme Court upholds legality of patent review process.NEWS2: Gilead Sciences Focuses on Its Liver Disease Portfolio.NEWS3: Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down.NEWS4: Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down.NEWS5: Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings?.NEWS6: Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings?.NEWS7: Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings?.NEWS8: Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down.NEWS9: How Does Biogen Make its Money?.NEWS10: U.S. Supreme Court upholds legality of patent review process.NEWS11: What's in Store for AmerisourceBergen (ABC) in Q2 Earnings?.NEWS12: What's in Store for AmerisourceBergen (ABC) in Q2 Earnings?.NEWS13: U.S. Supreme Court upholds legality of patent review process.NEWS14: Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma.NEWS15: Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma.NEWS16: This Small Biotech Is Building on a Surprising Success.NEWS17: Can PBM Unit Boost Express Scripts' (ESRX) Q1 Earnings?.NEWS18: Can PBM Unit Boost Express Scripts' (ESRX) Q1 Earnings?.NEWS19: Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma.NEWS20: Amid drug price worries, earnings to test U.S. pharma, biotech shares.NEWS21: Modern Miracles: America's 10 Best-Selling Drugs.NEWS22: Modern Miracles: America's 10 Best-Selling Drugs.
2018-04-25: NEWS1: Pre-Market Earnings Report for April 26, 2018 :  ABBV, PEP, MO, UNP, BMY, COP, TWX, UPS, RTN, CME, GM, ITW.NEWS2: Pre-Market Earnings Report for April 26, 2018 :  ABBV, PEP, MO, UNP, BMY, COP, TWX, UPS, RTN, CME, GM, ITW.NEWS3: Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX.NEWS4: Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX.NEWS5: What's in the Cards for Inogen (INGN) This Earnings Season?.NEWS6: What's in the Cards for Inogen (INGN) This Earnings Season?.NEWS7: Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX.NEWS8: Shire willing to back $64 billion Takeda bid, market signals doubts.NEWS9: AbbVie Submits Biologics License Application to U.S. FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis.NEWS10: A Look at Biogen’s Performance in 1Q18.NEWS11: AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients.NEWS12: Why Incyte Stock Fell ~9% on April 24.NEWS13: Gilead Sciences’ Inflammation Research Is Seeing Rapid Progress.NEWS14: Supreme Court upholds legality of patent review process.
2018-04-26: NEWS1: What Analysts Recommend for Neurocrine Biosciences in April 2018.NEWS2: Notable Thursday Option Activity: MAR, GILD, ABBV.NEWS3: Notable Thursday Option Activity: MAR, GILD, ABBV.NEWS4: How AbbVie &apos;Crushed It&apos; On Hepatitis C As Fellow Drugmaker Bristol Dips.NEWS5: Health Care Sector Update for 04/26/2018: ALXN,AXSM,ABBV,BMY.NEWS6: Health Care Sector Update for 04/26/2018: ALXN,AXSM,ABBV,BMY.NEWS7: AbbVie Inc Stock Up on Strong Earnings, Guidance Update.NEWS8: AbbVie Inc Stock Up on Strong Earnings, Guidance Update.NEWS9: Abbvie Up over 6% on 1Q18 Earnings Beat, Raised Earnings Forecast.NEWS10: DaVIta (DVA) to Report Q1 Earnings: Is a Beat in Store?.NEWS11: DaVIta (DVA) to Report Q1 Earnings: Is a Beat in Store?.NEWS12: Markets Now: Dow Gains 300 Points as Market Realizes Earnings Are Really, Really Good.NEWS13: Markets Now: Dow Gains 300 Points as Market Realizes Earnings Are Really, Really Good.NEWS14: AbbVie Inc. -- Moody's: AbbVie's share repurchase acceleration credit negative.NEWS15: AbbVie (ABBV) Q1 Earnings Beat, 2018 View Up, Stock Gains.NEWS16: AbbVie (ABBV) Q1 Earnings Beat, 2018 View Up, Stock Gains.NEWS17: Health Care Sector Update for 04/26/2018: ABBV,AXSM.NEWS18: Health Care Sector Update for 04/26/2018: ABBV,AXSM.NEWS19: There are a lot of 'table-pounding buys' in the market now: Value investor David Katz.NEWS20: DaVIta (DVA) to Report Q1 Earnings: Is a Beat in Store?.NEWS21: Is a Beat in the Cards for Gilead (GILD) in Q1 Earnings?.NEWS22: Is a Beat in the Cards for Gilead (GILD) in Q1 Earnings?.NEWS23: AbbVie Breaks Above 200-Day Moving Average - Bullish for ABBV.NEWS24: AbbVie Breaks Above 200-Day Moving Average - Bullish for ABBV.NEWS25: A Look At The Intrinsic Value Of AbbVie Inc (NYSE:ABBV).NEWS26: AbbVie (ABBV) Q1 Earnings Beat, 2018 View Up, Stock Gains.NEWS27: AbbVie Inc Stock Up on Strong Earnings, Guidance Update.NEWS28: Is a Beat in the Cards for Gilead (GILD) in Q1 Earnings?.NEWS29: Sales Of AbbVie's Hepatitis C Drugs Soar.NEWS30: AbbVie (ABBV) Tops Q1 Earnings and Revenues, View Up.NEWS31: AbbVie (ABBV) Tops Q1 Earnings and Revenues, View Up.NEWS32: Drug Makers: A Dose of Robust Earnings.NEWS33: Analyst Recommendations for Biogen in April.NEWS34: AbbVie (ABBV) Tops Q1 Earnings and Revenues, View Up.NEWS35: [$$] AbbVie unveils $7.5bn share buyback.NEWS36: How AbbVie &apos;Crushed It&apos; On Hepatitis C As Fellow Drugmaker Bristol Dips.NEWS37: AbbVie, Bristol-Myers Top Earnings Views, But Bristol Sales Missed.NEWS38: AbbVie: 1Q Earnings Snapshot.NEWS39: AbbVie shares rise 3% on Q1 profit, revenue beats and $7.5 billion share buyback.NEWS40: AbbVie beats quarterly revenue estimates, raises earnings forecast.NEWS41: AbbVie Reports First-Quarter 2018 Financial Results.NEWS42: Earnings Reaction History: AbbVie Inc., 54.5% Follow-Through Indicator, 4.4% Sensitive.NEWS43: Earnings Reaction History: AbbVie Inc., 54.5% Follow-Through Indicator, 4.4% Sensitive.
2018-04-27: NEWS1: 9 Highest-Yielding Dividend Aristocrats to Buy Today.NEWS2: 9 Highest-Yielding Dividend Aristocrats to Buy Today.NEWS3: HIV Segment to Aid Gilead (GILD) Beat Q1 Earnings Estimates?.NEWS4: HIV Segment to Aid Gilead (GILD) Beat Q1 Earnings Estimates?.NEWS5: 3 Things You Need to Know About AbbVie's Monster Q1 Earnings.NEWS6: 3 Things You Need to Know About AbbVie's Monster Q1 Earnings.NEWS7: 3 Things You Need to Know About AbbVie&apos;s Monster Q1 Earnings.NEWS8: AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting.NEWS9: AbbVie Presents New Investigational Data For Elagolix.NEWS10: AbbVie Presents New Investigational Data For Elagolix.NEWS11: Edited Transcript of ABBV earnings conference call or presentation 26-Apr-18 1:00pm GMT.

Answer: Decrease